IGM Biosciences Net Worth
IGM Biosciences Net Worth Breakdown | IGMS |
IGM Biosciences Net Worth Analysis
IGM Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including IGM Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of IGM Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform IGM Biosciences' net worth analysis. One common approach is to calculate IGM Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares IGM Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing IGM Biosciences' net worth. This approach calculates the present value of IGM Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of IGM Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate IGM Biosciences' net worth. This involves comparing IGM Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into IGM Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if IGM Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding IGM Biosciences' net worth research are outlined below:
| IGM Biosciences generated a negative expected return over the last 90 days | |
| IGM Biosciences may become a speculative penny stock | |
| IGM Biosciences has high historical volatility and very poor performance | |
| IGM Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.68 M. Net Loss for the year was (195.79 M) with loss before overhead, payroll, taxes, and interest of (129.42 M). | |
| IGM Biosciences currently holds about 469.14 M in cash with (153 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Concentra Group to Acquire IGM Biosciences - MSN |
IGM Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in IGM Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to IGM Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know IGM Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IGM Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IGM Biosciences backward and forwards among themselves. IGM Biosciences' institutional investor refers to the entity that pools money to purchase IGM Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2025-03-31 | 187 K | Two Sigma Investments Llc | 2025-03-31 | 139.8 K | Charles Schwab Investment Management Inc | 2025-03-31 | 125.6 K | Verition Fund Managegment, Llc | 2025-03-31 | 119.1 K | Bruce & Co Inc | 2025-03-31 | 100 K | Eagle Bay Advisors Llc | 2025-06-30 | 99.6 K | Two Sigma Advisers, Llc | 2025-03-31 | 90.5 K | Acadian Asset Management Llc | 2025-03-31 | 85.8 K | Woodline Partners Lp | 2025-03-31 | 69.6 K | Baker Bros Advisors Lp | 2025-03-31 | 4.1 M | Siren, L.l.c. | 2025-03-31 | 3.3 M |
Follow IGM Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.04 M.Market Cap |
|
Project IGM Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.74) | (0.77) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.74) | (0.77) | |
| Return On Equity | (4.06) | (3.86) |
When accessing IGM Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures IGM Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of IGM Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in IGM Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IGM Biosciences. Check IGM Biosciences' Beneish M Score to see the likelihood of IGM Biosciences' management manipulating its earnings.
Evaluate IGM Biosciences' management efficiency
IGM Biosciences has return on total asset (ROA) of (0.3678) % which means that it has lost $0.3678 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4559) %, meaning that it created substantial loss on money invested by shareholders. IGM Biosciences' management efficiency ratios could be used to measure how well IGM Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.77 in 2025. Return On Capital Employed is likely to drop to -0.96 in 2025. At this time, IGM Biosciences' Total Assets are comparatively stable compared to the past year. Other Assets is likely to gain to about 2.4 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 47.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.80 | 0.84 | |
| Tangible Book Value Per Share | 0.80 | 0.84 | |
| Enterprise Value Over EBITDA | (1.95) | (2.04) | |
| Price Book Value Ratio | 7.68 | 8.06 | |
| Enterprise Value Multiple | (1.95) | (2.04) | |
| Price Fair Value | 7.68 | 8.06 | |
| Enterprise Value | 388.4 M | 508.7 M |
IGM Biosciences has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 277.3705 | Revenue | Quarterly Revenue Growth 0.004 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IGM Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on IGM Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IGM Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IGM Biosciences time-series forecasting models is one of many IGM Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary IGM Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
IGM Biosciences Earnings per Share Projection vs Actual
IGM Biosciences Corporate Management
| TS Harigopal | Senior Operations | Profile | |
| Faraz Siddiqui | Senior Operations | Profile | |
| Angus Sinclair | Senior ImmunoOncology | Profile | |
| Elizabeth JD | Senior Property | Profile | |
| Elaine Sapinoso | Senior Quality | Profile | |
| Misbah CPA | Chief Officer | Profile | |
| Lisa Decker | Chief Officer | Profile |
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.